Nikhil Lalwani Sells 33,481 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ANI Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ ANIP traded up $1.53 during trading hours on Wednesday, hitting $59.39. The stock had a trading volume of 228,701 shares, compared to its average volume of 218,832. The company has a market capitalization of $1.25 billion, a P/E ratio of -105.20 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm’s 50-day moving average price is $58.32 and its two-hundred day moving average price is $60.76. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company’s revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.05 earnings per share. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the subject of several research analyst reports. Raymond James upped their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Innealta Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $65,000. Ridgewood Investments LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at $85,000. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at $106,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at $218,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.